Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV
Source: infectiousdiseaseadvisor.com Although adding ibalizumab to an optimized background regimen of antiretroviral therapy (ART) is not cost-effective, ibalizumab substantially increased […]